Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct

Robert Stratford Jr., Christopher Vu, Joshua Sakon, Ranjitha Katikaneni, Robert Gensure, Tulasi Ponnapakkam

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The pharmacokinetics of a hybrid peptide consisting of the N-terminal biologically active region of human parathyroid hormone (PTH) linked to a collagen-binding domain (CBD) were evaluated in female Sprague-Dawley rats. The peptide, PTH-CBD, consists of the first 33 amino acids of PTH linked as an extension of the amino acid chain to the CBD peptide derived from ColH collagenase of Clostridium histolyticum. Serum concentrations arising from single dose administration by the subcutaneous and intravenous routes were compared with those measured following route-specific mole equivalent doses of PTH(1-34). Population-based modeling demonstrated similar systemic absorption kinetics and bioavailability for both peptides. Exposure to PTH-CBD was sixfold higher because of a systemic clearance of approximately 20% relative to PTH(1-34); however, these kinetics were consistent with more than 95% of a dose being eliminated from serum within 24 h. Results obtained support continued investigation of PTH-CBD as a bone-targeted anabolic agent for the treatment of postmenopausal osteoporosis.

Original languageEnglish (US)
Pages (from-to)768-775
Number of pages8
JournalJournal of Pharmaceutical Sciences
Volume103
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Parathyroid Hormone
Collagen
Pharmacokinetics
Microbial Collagenase
Anabolic Agents
Amino Acids
Peptides
Postmenopausal Osteoporosis
Peptide Hormones
Serum
Intravenous Administration
Biological Availability
Sprague Dawley Rats
Protein Domains
human PTH protein
Bone and Bones
Population

Keywords

  • Collagen binding
  • Osteoporosis
  • Peptide delivery
  • Peptides
  • Pharmacokinetic/pharmacodynamic models
  • Population pharmacokinetics
  • Preclinical pharmacokinetics
  • PTH(1-34)
  • Teriparatide

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct. / Stratford Jr., Robert; Vu, Christopher; Sakon, Joshua; Katikaneni, Ranjitha; Gensure, Robert; Ponnapakkam, Tulasi.

In: Journal of Pharmaceutical Sciences, Vol. 103, No. 2, 01.01.2014, p. 768-775.

Research output: Contribution to journalArticle

Stratford Jr., Robert ; Vu, Christopher ; Sakon, Joshua ; Katikaneni, Ranjitha ; Gensure, Robert ; Ponnapakkam, Tulasi. / Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct. In: Journal of Pharmaceutical Sciences. 2014 ; Vol. 103, No. 2. pp. 768-775.
@article{fb6370932bc8407b94238fe6a83e338e,
title = "Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct",
abstract = "The pharmacokinetics of a hybrid peptide consisting of the N-terminal biologically active region of human parathyroid hormone (PTH) linked to a collagen-binding domain (CBD) were evaluated in female Sprague-Dawley rats. The peptide, PTH-CBD, consists of the first 33 amino acids of PTH linked as an extension of the amino acid chain to the CBD peptide derived from ColH collagenase of Clostridium histolyticum. Serum concentrations arising from single dose administration by the subcutaneous and intravenous routes were compared with those measured following route-specific mole equivalent doses of PTH(1-34). Population-based modeling demonstrated similar systemic absorption kinetics and bioavailability for both peptides. Exposure to PTH-CBD was sixfold higher because of a systemic clearance of approximately 20{\%} relative to PTH(1-34); however, these kinetics were consistent with more than 95{\%} of a dose being eliminated from serum within 24 h. Results obtained support continued investigation of PTH-CBD as a bone-targeted anabolic agent for the treatment of postmenopausal osteoporosis.",
keywords = "Collagen binding, Osteoporosis, Peptide delivery, Peptides, Pharmacokinetic/pharmacodynamic models, Population pharmacokinetics, Preclinical pharmacokinetics, PTH(1-34), Teriparatide",
author = "{Stratford Jr.}, Robert and Christopher Vu and Joshua Sakon and Ranjitha Katikaneni and Robert Gensure and Tulasi Ponnapakkam",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/jps.23843",
language = "English (US)",
volume = "103",
pages = "768--775",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct

AU - Stratford Jr., Robert

AU - Vu, Christopher

AU - Sakon, Joshua

AU - Katikaneni, Ranjitha

AU - Gensure, Robert

AU - Ponnapakkam, Tulasi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The pharmacokinetics of a hybrid peptide consisting of the N-terminal biologically active region of human parathyroid hormone (PTH) linked to a collagen-binding domain (CBD) were evaluated in female Sprague-Dawley rats. The peptide, PTH-CBD, consists of the first 33 amino acids of PTH linked as an extension of the amino acid chain to the CBD peptide derived from ColH collagenase of Clostridium histolyticum. Serum concentrations arising from single dose administration by the subcutaneous and intravenous routes were compared with those measured following route-specific mole equivalent doses of PTH(1-34). Population-based modeling demonstrated similar systemic absorption kinetics and bioavailability for both peptides. Exposure to PTH-CBD was sixfold higher because of a systemic clearance of approximately 20% relative to PTH(1-34); however, these kinetics were consistent with more than 95% of a dose being eliminated from serum within 24 h. Results obtained support continued investigation of PTH-CBD as a bone-targeted anabolic agent for the treatment of postmenopausal osteoporosis.

AB - The pharmacokinetics of a hybrid peptide consisting of the N-terminal biologically active region of human parathyroid hormone (PTH) linked to a collagen-binding domain (CBD) were evaluated in female Sprague-Dawley rats. The peptide, PTH-CBD, consists of the first 33 amino acids of PTH linked as an extension of the amino acid chain to the CBD peptide derived from ColH collagenase of Clostridium histolyticum. Serum concentrations arising from single dose administration by the subcutaneous and intravenous routes were compared with those measured following route-specific mole equivalent doses of PTH(1-34). Population-based modeling demonstrated similar systemic absorption kinetics and bioavailability for both peptides. Exposure to PTH-CBD was sixfold higher because of a systemic clearance of approximately 20% relative to PTH(1-34); however, these kinetics were consistent with more than 95% of a dose being eliminated from serum within 24 h. Results obtained support continued investigation of PTH-CBD as a bone-targeted anabolic agent for the treatment of postmenopausal osteoporosis.

KW - Collagen binding

KW - Osteoporosis

KW - Peptide delivery

KW - Peptides

KW - Pharmacokinetic/pharmacodynamic models

KW - Population pharmacokinetics

KW - Preclinical pharmacokinetics

KW - PTH(1-34)

KW - Teriparatide

UR - http://www.scopus.com/inward/record.url?scp=84895927317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895927317&partnerID=8YFLogxK

U2 - 10.1002/jps.23843

DO - 10.1002/jps.23843

M3 - Article

C2 - 24399637

AN - SCOPUS:84895927317

VL - 103

SP - 768

EP - 775

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 2

ER -